Role of adjuvant therapy in surgically resected colorectal carcinoma

Gastroenterology

Volumn 109, Issue 3, 1995, Pages 984-993

  Sinicrope, Frank A ^a   Sugarman, Steven M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; INTERFERON; IRINOTECAN; LEVAMISOLE; UFT;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE METASTASIS; MORTALITY; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMATITIS; SURVIVAL RATE;

EID: 0029088471     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(95)90410-7     Document Type: Article

References (78)

1. Cancer statistics
2. Staging of cancer of the colon and rectum
3. Adjuvant Therapy for Patients With Colon and Rectal Cancer
4. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
5. Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery
6. Adjuvant therapy for stage III colon cancer: economic returns to research and cost-effectiveness of treatment
7. The Use of 5-Fluorodeoxy uridine (FUDR) as a Surgical Adjuvant in Carcinoma of the Stomach and Colorectum
8. FUDR as an adjuvant to surgery in cancer of the large bowel
9. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled randomized trial
10. The case for adjuvant 5-fluorouracil in colorectal cancer
11. Adjuvant therapy of colorectal cancer: why we still don't know
12. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and me-CCNU following resection for carcinomas of the large bowel
13. Adjuvant Therapy of Colon Cancer — Results of a Prospectively Randomized Trial
14. Adjuvant studies in colorectal carcinoma: experience of The Eastern Cooperative Oncology Group (ECOG) preliminary report
15. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01
16. Leukemia and pre-leukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)
17. The levamisole story
18. The general immunopharmacology of levamisole
19. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma
20. Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma
21. Sequential chemoimmunotherapy of colorectal cancer
22. Postoperative levamisole in colorectal cancer
23. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial
24. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil
25. Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report
26. Does adjuvant therapy work in colon cancer?
27. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells
28. Absence of biologic effects with levamisole treatment
29. Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma
30. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
31. An Intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer
32. FUFA increases disease-free survival (DFS) in resected B2C colon cancer (CC): results of a prospective pooled analysis of 3 randomized trials
33. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
34. Preclinical and clinical studies of 5-fluorouracil (FUra) and recombinant alpha-2A-interferon against gastrointestinal (GI) malignancies
35. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer
36. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma
37. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma
38. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced carcinoma
39. Phase I trial of 5-fluorouracil and recombinant alfa-2a-interferon in patients with advanced colorectal carcinoma
40. Phase II trial of fluorouracil and recombinant interferon alpha-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study
41. A randomized phase III trial comparing 5-FU with or without interferon alfa-2a for advanced colorectal cancer
42. 5-Fluorouracil (5-FU) plus interferon alfa-2a (Roferon-A) vs 5-FU plus leucovorin (LV) in metastatic colorectal cancer
43. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma
44. Flourouracil (5-FU) and folinic acid (FA) with or without a2b-interferon in advanced colorectal cancer: a prospective randomized trial
45. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial
46. Vaccine adjuvant therapy for colorectal cancer: very dramatic or ho-hum
47. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
48. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer
49. Adjuvant therapy of Duke's A, B and C adenocarcinoma of the colon with portalvein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02
50. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer
51. Adjuvant intraportal chemotherapy of colorectal cancer: 4-year results of the randomized Swiss study (Sakk 40/81)
52. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01
53. Pharmacologic requirements for obtaining radiation sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x-rays
54. Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
55. Survival after post-operative combination treatment of rectal cancer
56. Effective surgical adjuvant therapy for high risk rectal carcinoma
57. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
58. Antimetabolites
59. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole
60. Multifocal Leukoencephalopathy: Occurrence During 5-Fluorouracil and Levamisole Therapy and Resolution After Discontinuation of Chemotherapy
61. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy
62. Phase II study of CPT-11, a new campothecin derivative, in metastatic colorectal cancer
63. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma
64. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma
65. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern
66. DNA distribution in human colon carcinomas and its relationship to clinical behavior
67. The influence of tumor cell DNA abnormalities on survival in colorectal cancer
68. Tumor DNA Content in the Prognosis of Colorectal Carcinoma
69. Genetic alterations during colorectal tumor development
70. Association of p53 mutations with short survival in colorectal cancer
71. Clinical and pathological associations with allelic loss in colorectal carcinoma
72. Overexpression of p53 and long-term survival in colon carcinoma
73. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients.
74. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
75. Allelic loss of chromosome 18q and prognosis in colorectal cancer
76. The role of thymidylate synthase in predicting response and survival in tumors of the gastrointestinal tract
77. Thymidylate synthetase expression is an independent predictor of survival/disease-free survival in patients with rectal cancer
78. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil